Latest news

24.Mar 21

Scandion Oncology is recruiting a Financial Controller
Be our new Financial Controller in a biotech company f...

18.Mar 21

Invest Talks
Read the interview (in Swedish) with CEO Bo Rode Hansen featured in today’s “...

20.Feb 21

Great interest at our Year-end 2020 webcast
Thank you to all attendees who joined our live Year-end 2020 webcast & Q&...

18.Feb 21

Invitation to Scandion Oncology A/S live webcast on February 19, 2021
Invitation to Scandion Oncology A/S live webcast on February 19, 2021 We h...

04.Feb 21

A great milestone
A great milestone: On Feb. 3rd, 2021, Scandion Oncology was listed as company...

18.Dec 20

Scandion Oncology tackles antioestrogen resistance
Scandion Oncology is currently evaluating its lead candidate SCO-101 ...

18.Dec 20

Dansk lægemiddel ser ud til at bekæmpe resistens på tværs af kræftsygdomme
SABCS: Cellelinjer og farmakodynamiske studier peger på, at præparate...

20.Nov 20

+200 attendees joined our webcast today
Thank you to the +200 interested attendees that joined our live webcast today...

19.Nov 20

Invitation to Scandion Oncology A/S live webcast on 20 November 2020
Invitation to Scandion Oncology A/S live webcast on 20 November 2020 We ha...

19.Nov 20

CEO Bo Rode Hansen interviewed by MedWatch about rights issue
CEO Bo Rode Hansen has been intervi...

Load more (78)
Scandion Oncology A/S

Symbion
Fruebjergvej 3
DK – 2100 Copenhagen
Denmark

Social media

Linkedin
Twitter

Press

Bo Rode Hansen, President & CEO
E: info@scandiononcology.com
P: +45 38 10 20 17

Stay updated with our newsletter

Get notified on mail, when news or press release is posted on our website.

Privacy and Cookie Policy